生命科学资讯

Moderna offloads late-stage rare disease drug to Recordati for $50M upfront

AstraZeneca returns to China's CSPC for $18.5B obesity deal

Janux hires CMO after T cell engager deal with Bristol Myers; A batch of appointments at Lexeo

Mutual of America Capital Management LLC Sells 12,121 Shares of Agilent Technologies, Inc. $A - MarketBeat

Reed Jobs' cancer biotech investment firm Yosemite eyes $350M fund

AstraZeneca pays $1.2B for CSPC's long-acting obesity drugs

A Long-Read Duopoly – PacBio or Oxford Nanopore? - Nanalyze

Thermo Fisher Scientific Q4 Earnings Call Highlights - Yahoo Finance

Causal evidence for a domain-specific role of left superior frontal sulcus in human perceptual decision-making

Lonza reports strong growth in 2025 - thereporter.com

The Truth About Illumina Inc.: Is This DNA Giant Still Worth Your Money or Is the Hype Over? - AD HOC NEWS

Up and Down Morning for Thermo Fisher Scientific - wfmz.com

Formation Bio’s China shopping spree continues with $500M biobucks autoimmune pact

The biopharma industry outlook on 2026: Optimism and tension

Takeda 'anticipated' Medicare negotiations for top seller Entyvio

As humans return to the Moon, scientists confront the dangers of deep-space radiation

Roche Expands Clinical Research in Mexico, Invests MX$1.2 Billion - Mexico Business News

Takeda is ‘not in favor’ of Trump’s MFN deals, CEO-designate says

White House postpones planned TrumpRx launch event

Lonza Group Continues To Leverage Biopharma’s Optimization Push (OTCMKTS:LZAGY) - Seeking Alpha